ArticleACS omega2025
A Levodopa-Encapsulated Poly-ε-Caprolactone Nanocomposite Improves the Motor Symptoms and Neurochemical Changes in a Rotenone-Induced Mouse Model of Parkinson's Disease.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Optimization of the Nanoparticle Yield and Physicochemical Properties by a Structured Study of Nanoprecipitation Process Parameters.ACS omega · 2026Article
- From Bench to Brain: Translating EV and Nanocarrier Research into Parkinson's Disease Therapies.Biology · 2025Review
- A novel nanocomposite Lf-DA-MSN-PF127 aided the delivery of dopamine for the treatment of Parkinson's disease in a rat model.Nanoscale advances · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease (PD) is the most common neurodegenerative disorder; in this condition, patients lose dopamine (DA), which leads to abnormal motor functions. Levodopa (LD) is the most effective drug used for the treatment of PD; however, LD shows poor plasma bioavailability and limited brain uptake and induces peripheral side effects. Due to its poor brain availability and short half-life, prolonged treatment must be repeated with a dosing schedule, which leads to long-term side effects, including dyskinesia, stomatitis, anxiety, and depression. An LD-encapsulated polymer nanocomposite has been reported to overcome these problems. The present study aims to improve the bioavailability and efficiency of LD to an effective treatment strategy for PD. Herein, we report the newly synthesized LD-encapsulated poly-ε-caprolactone (PCL) nanocomposite (LD-PCL-PVA NC), and its chemical and physical properties were analyzed. The LD-PCL-PVA NC exhibits no toxicity on the SH-SY5Y cell line and shows improved bioavailability of the LD in mouse plasma. Furthermore, we found that LD-PCL-PVA NC showed a significant improvement in motor symptoms in the rotenone (RT)-induced PD mouse model compared to the LD treatment. In addition, LD-PCL-PVA NC significantly increased the DA and homovanillic acid compared to LD and restored the total glutathione level and malonaldehyde and catalase activity in mouse brain. The histopathology studies reveal that LD-PCL-PVA NC did not exhibit toxicity in treated mice. The study suggested that LD-PCL-PVA NC can be used for the effective and promising treatment of PD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.